sponsored

Imagine a healthcare system made up of multiple AI agents: one that manages symptom assessment, another scheduling, a third insurance, and a fourth pharmacy. Each is an expert in its domain. But they all have their own distinct knowledge and objectives. Today they can exchange data, but they are not yet able to actually coordinate

Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs

For the enterprise, the promise of agentic AI is much more than just a better chatbot. It is software agents that execute business tasks end-to-end across people, business workflows, data, and systems. The platform best-suited to run agents is built with proper CPU capacity, resilient data access, policy-aware tool use, observability, memory management, and the

Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are often used to

The conversation about AI often centers on algorithms, computing power, or huge investments in new semiconductor fabrication plants and hyperscale data centers. But beneath each of these advances is another layer of innovation that makes them possible: advanced materials. Every new generation of AI technology demands more processing power, more memory, greater energy efficiency, and